Epigenetic alterations in acute myeloid leukemias

FEBS Journal

Volumn 282, Issue 9, 2015, Pages 1786-1800

  Mehdipour, Parinaz ^a   Santoro, Fabio ^a   Minucci, Saverio ^a,b  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

AML; APL; cancer stem cells; epi drugs; epigenetic alterations

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; COHESIN; DIOXYGENASE; DNA METHYLTRANSFERASE 3A; ENTINOSTAT; GIVINOSTAT; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HYBRID PROTEIN; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; MIXED LINEAGE LEUKEMIA PROTEIN; MOCETINOSTAT; PANOBINOSTAT; PROMYELOCYTIC LEUKEMIA PROTEIN; RESMINOSTAT; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; ROMIDEPSIN; TET1 PROTEIN; TET2 PROTEIN; TET3 PROTEIN; TRANSCRIPTION FACTOR HOXA9; TRANSCRIPTION FACTOR RUNX1; TRANYLCYPROMINE; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; AML1 ETO GENE; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASXL1 GENE; CANCER STEM CELL; CHROMOSOME TRANSLOCATION; CPG ISLAND; CUTANEOUS T CELL LYMPHOMA; DNA METHYLATION; DNA MODIFICATION; DNMT3A GENE; DRUG SELECTIVITY; EPIGENETICS; FUSION GENE; GENE MUTATION; HUMAN; LARGE CELL LYMPHOMA; MOLECULARLY TARGETED THERAPY; MYELODYSPLASTIC SYNDROME; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PML RARA GENE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN MOTIF; TET1 GENE; TET2 GENE; TET3 GENE; TRANSCRIPTION INITIATION; TRANSCRIPTION TERMINATION; GENETIC EPIGENESIS; GENETICS; LEUKEMIA, MYELOID, ACUTE;

ANTINEOPLASTIC AGENTS; EPIGENESIS, GENETIC; HUMANS; LEUKEMIA, MYELOID, ACUTE;

EID: 84928533993     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.13142     Document Type: Article

References (124)

1. Dohner K, &, Dohner H, (2008) Molecular characterization of acute myeloid leukemia. Haematologica 93, 976-982.
2. Marcucci G, Haferlach T, &, Dohner H, (2011) Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol 29, 475-486.
3. O'Brien CP, Langabeer SE, O'Byrne KJ, O'Leary JJ, &, Finn SP, (2014) Predictive values for molecular diagnostics: converting unknown unknowns to known unknowns. Mol Diagn Ther 18, 1-4.
4. Sweet K, &, Lancet JE, (2014) Novel therapeutics in acute myeloid leukemia. Curr Hematol Malig Rep 9, 109-117.
5. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, et al.,. (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115, 453-474.
6. Verhaak RG, Wouters BJ, Erpelinck CA, Abbas S, Beverloo HB, Lugthart S, Lowenberg B, Delwel R, &, Valk PJ, (2009) Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling. Haematologica 94, 131-134.
7. Bain BJ, (1998) Classification of acute leukaemia: the need to incorporate cytogenetic and molecular genetic information. J Clin Pathol 51, 420-423.
8. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, &, Sultan C, (1976) Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 33, 451-458.
9. Vardiman JW, Harris NL, &, Brunning RD, (2002) The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100, 2292-2302.
10. Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioglu A, Bullinger L, Habdank M, Spath D, Morgan M, Benner A, et al.,. (2008) Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 358, 1909-1918.
11. Corces-Zimmerman MR, Hong WJ, Weissman IL, Medeiros BC, &, Majeti R, (2014) Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci USA 111, 2548-2553.
12. Garraway LA, &, Lander ES, (2013) Lessons from the cancer genome. Cell 153, 17-37.
13. Sharma S, Kelly TK, &, Jones PA, (2010) Epigenetics in cancer. Carcinogenesis 31, 27-36.
14. Goelz SE, Vogelstein B, Hamilton SR, &, Feinberg AP, (1985) Hypomethylation of DNA from benign and malignant human colon neoplasms. Science 228, 187-190.
15. Esteller M, (2007) Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 8, 286-298.
16. Nguyen C, Liang G, Nguyen TT, Tsao-Wei D, Groshen S, Lubbert M, Zhou JH, Benedict WF, &, Jones PA, (2001) Susceptibility of nonpromoter CpG islands to de novo methylation in normal and neoplastic cells. J Natl Cancer Inst 93, 1465-1472.
17. Sadikovic B, Al-Romaih K, Squire JA, &, Zielenska M, (2008) Cause and consequences of genetic and epigenetic alterations in human cancer. Curr Genomics 9, 394-408.
18. Akalin A, Garrett-Bakelman FE, Kormaksson M, Busuttil J, Zhang L, Khrebtukova I, Milne TA, Huang Y, Biswas D, Hess JL, et al.,. (2012) Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia. PLoS Genet 8, e1002781.
19. Deneberg S, Guardiola P, Lennartsson A, Qu Y, Gaidzik V, Blanchet O, Karimi M, Bengtzen S, Nahi H, Uggla B, et al.,. (2011) Prognostic DNA methylation patterns in cytogenetically normal acute myeloid leukemia are predefined by stem cell chromatin marks. Blood 118, 5573-5582.
20. Figueroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos PJ, Schifano E, Booth J, van Putten W, Skrabanek L, et al.,. (2010) DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 17, 13-27.
21. Baylin SB, &, Jones PA, (2011) A decade of exploring the cancer epigenome-biological and translational implications. Nat Rev Cancer 11, 726-734.
22. Elsheikh SE, Green AR, Rakha EA, Powe DG, Ahmed RA, Collins HM, Soria D, Garibaldi JM, Paish CE, Ammar AA, et al.,. (2009) Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res 69, 3802-3809.
23. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, Bonaldi T, Haydon C, Ropero S, Petrie K, et al.,. (2005) Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37, 391-400.
24. Barlesi F, Giaccone G, Gallegos-Ruiz MI, Loundou A, Span SW, Lefesvre P, Kruyt FA, &, Rodriguez JA, (2007) Global histone modifications predict prognosis of resected non small-cell lung cancer. J Clin Oncol 25, 4358-4364.
25. Manuyakorn A, Paulus R, Farrell J, Dawson NA, Tze S, Cheung-Lau G, Hines OJ, Reber H, Seligson DB, Horvath S, et al.,. (2010) Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704. J Clin Oncol 28, 1358-1365.
26. Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M, &, Kurdistani SK, (2005) Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435, 1262-1266.
27. You JS, &, Jones PA, (2012) Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell 22, 9-20.
28. Di Croce L, Raker VA, Corsaro M, Fazi F, Fanelli M, Faretta M, Fuks F, Lo Coco F, Kouzarides T, Nervi C, et al.,. (2002) Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 295, 1079-1082.
29. Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M, Fanelli M, Ruthardt M, Ferrara FF, Zamir I, et al.,. (1998) Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 391, 815-818.
30. Lin RJ, Nagy L, Inoue S, Shao W, Miller WH Jr, &, Evans RM, (1998) Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 391, 811-814.
31. Zhou J, Peres L, Honore N, Nasr R, Zhu J, &, de The H, (2006) Dimerization-induced corepressor binding and relaxed DNA-binding specificity are critical for PML/RARA-induced immortalization. Proc Natl Acad Sci USA 103, 9238-9243.
32. Minucci S, &, Pelicci PG, (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6, 38-51.
33. Villa R, Pasini D, Gutierrez A, Morey L, Occhionorelli M, Vire E, Nomdedeu JF, Jenuwein T, Pelicci PG, Minucci S, et al.,. (2007) Role of the polycomb repressive complex 2 in acute promyelocytic leukemia. Cancer Cell 11, 513-525.
34. Fenaux P, Le Deley MC, Castaigne S, Archimbaud E, Chomienne C, Link H, Guerci A, Duarte M, Daniel MT, Bowen D, et al.,. (1993) Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood 82, 3241-3249.
35. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, Gu LJ, &, Wang ZY, (1988) Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72, 567-572.
36. Licht JD, (2006) Reconstructing a disease: what essential features of the retinoic acid receptor fusion oncoproteins generate acute promyelocytic leukemia? Cancer Cell 9, 73-74.
37. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Willman C, Bloomfield CD, Rowe JM, et al.,. (1997) All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 337, 1021-1028.
38. Zhou GB, Zhao WL, Wang ZY, Chen SJ, &, Chen Z, (2005) Retinoic acid and arsenic for treating acute promyelocytic leukemia. PLoS Med 2, e12.
39. Mathews V, George B, Chendamarai E, Lakshmi KM, Desire S, Balasubramanian P, Viswabandya A, Thirugnanam R, Abraham A, Shaji RV, et al.,. (2010) Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J Clin Oncol 28, 3866-3871.
40. Ablain J, &, de The H, (2011) Revisiting the differentiation paradigm in acute promyelocytic leukemia. Blood 117, 5795-5802.
41. Martens JH, Brinkman AB, Simmer F, Francoijs KJ, Nebbioso A, Ferrara F, Altucci L, &, Stunnenberg HG, (2010) PML-RARalpha/RXR alters the epigenetic landscape in acute promyelocytic leukemia. Cancer Cell 17, 173-185.
42. Peterson LF, &, Zhang DE, (2004) The 8;21 translocation in leukemogenesis. Oncogene 23, 4255-4262.
43. Hatlen MA, Wang L, &, Nimer SD, (2012) AML1-ETO driven acute leukemia: insights into pathogenesis and potential therapeutic approaches. Front Med 6, 248-262.
44. Mulloy JC, Cammenga J, MacKenzie KL, Berguido FJ, Moore MA, &, Nimer SD, (2002) The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells. Blood 99, 15-23.
45. Oki Y, &, Issa JP, (2010) Epigenetic mechanisms in AML-a target for therapy. Cancer Treat Res 145, 19-40.
46. Reikvam H, Hatfield KJ, Kittang AO, Hovland R, &, Bruserud O, (2011) Acute myeloid leukemia with the t(8;21) translocation: clinical consequences and biological implications. J Biomed Biotechnol 2011, 104631.
47. Maiques-Diaz A, Chou FS, Wunderlich M, Gomez-Lopez G, Jacinto FV, Rodriguez-Perales S, Larrayoz MJ, Calasanz MJ, Mulloy JC, Cigudosa JC, et al.,. (2012) Chromatin modifications induced by the AML1-ETO fusion protein reversibly silence its genomic targets through AML1 and Sp1 binding motifs. Leukemia 26, 1329-1337.
48. Wang L, Gural A, Sun XJ, Zhao X, Perna F, Huang G, Hatlen MA, Vu L, Liu F, Xu H, et al.,. (2011) The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation. Science 333, 765-769.
49. Becker H, Pfeifer D, Afonso JD, Nimer SD, Veelken H, Schwabe M, &, Lubbert M, (2008) Two cell lines of t(8;21) acute myeloid leukemia with activating KIT exon 17 mutation: models for the 'second hit' hypothesis. Leukemia 22, 1792-1794.
50. Muller AM, Duque J, Shizuru JA, &, Lubbert M, (2008) Complementing mutations in core binding factor leukemias: from mouse models to clinical applications. Oncogene 27, 5759-5773.
51. Wiemels JL, Xiao Z, Buffler PA, Maia AT, Ma X, Dicks BM, Smith MT, Zhang L, Feusner J, Wiencke J, et al.,. (2002) In utero origin of t(8;21) AML1-ETO translocations in childhood acute myeloid leukemia. Blood 99, 3801-3805.
52. Djabali M, Selleri L, Parry P, Bower M, Young BD, &, Evans GA, (1992) A trithorax-like gene is interrupted by chromosome 11q23 translocations in acute leukaemias. Nat Genet 2, 113-118.
53. Kourlas PJ, Strout MP, Becknell B, Veronese ML, Croce CM, Theil KS, Krahe R, Ruutu T, Knuutila S, Bloomfield CD, et al.,. (2000) Identification of a gene at 11q23 encoding a guanine nucleotide exchange factor: evidence for its fusion with MLL in acute myeloid leukemia. Proc Natl Acad Sci USA 97, 2145-2150.
54. Krivtsov AV, &, Armstrong SA, (2007) MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer 7, 823-833.
55. Xiao B, Wilson JR, &, Gamblin SJ, (2003) SET domains and histone methylation. Curr Opin Struct Biol 13, 699-705.
56. Milne TA, Briggs SD, Brock HW, Martin ME, Gibbs D, Allis CD, &, Hess JL, (2002) MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol Cell 10, 1107-1117.
57. Daser A, &, Rabbitts TH, (2004) Extending the repertoire of the mixed-lineage leukemia gene MLL in leukemogenesis. Genes Dev 18, 965-974.
58. Argiropoulos B, &, Humphries RK, (2007) Hox genes in hematopoiesis and leukemogenesis. Oncogene 26, 6766-6776.
59. Gutierrez SE, &, Romero-Oliva FA, (2013) Epigenetic changes: a common theme in acute myelogenous leukemogenesis. J Hematol Oncol 6, 57.
60. Marschalek R, (2010) Mixed lineage leukemia: roles in human malignancies and potential therapy. FEBS J 277, 1822-1831.
61. Cierpicki T, Risner LE, Grembecka J, Lukasik SM, Popovic R, Omonkowska M, Shultis DD, Zeleznik-Le NJ, &, Bushweller JH, (2010) Structure of the MLL CXXC domain-DNA complex and its functional role in MLL-AF9 leukemia. Nat Struct Mol Biol 17, 62-68.
62. Birke M, Schreiner S, Garcia-Cuellar MP, Mahr K, Titgemeyer F, &, Slany RK, (2002) The MT domain of the proto-oncoprotein MLL binds to CpG-containing DNA and discriminates against methylation. Nucleic Acids Res 30, 958-965.
63. Erfurth FE, Popovic R, Grembecka J, Cierpicki T, Theisler C, Xia ZB, Stuart T, Diaz MO, Bushweller JH, &, Zeleznik-Le NJ, (2008) MLL protects CpG clusters from methylation within the Hoxa9 gene, maintaining transcript expression. Proc Natl Acad Sci USA 105, 7517-7522.
64. Xia ZB, Anderson M, Diaz MO, &, Zeleznik-Le NJ, (2003) MLL repression domain interacts with histone deacetylases, the polycomb group proteins HPC2 and BMI-1, and the corepressor C-terminal-binding protein. Proc Natl Acad Sci USA 100, 8342-8347.
65. Lin C, Smith ER, Takahashi H, Lai KC, Martin-Brown S, Florens L, Washburn MP, Conaway JW, Conaway RC, &, Shilatifard A, (2010) AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. Mol Cell 37, 429-437.
66. Chang MJ, Wu H, Achille NJ, Reisenauer MR, Chou CW, Zeleznik-Le NJ, Hemenway CS, &, Zhang W, (2010) Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenes. Cancer Res 70, 10234-10242.
67. Nguyen AT, &, Zhang Y, (2011) The diverse functions of Dot1 and H3K79 methylation. Genes Dev 25, 1345-1358.
68. Nie Z, Xue Y, Yang D, Zhou S, Deroo BJ, Archer TK, &, Wang W, (2000) A specificity and targeting subunit of a human SWI/SNF family-related chromatin-remodeling complex. Mol Cell Biol 20, 8879-8888.
69. Zeisig BB, Arteaga MF, Thirant C, &, So CW, (2011) Collaboration between PcG proteins and MLL fusions in Leukemogenesis: an emerging paradigm. Cancer Cell 20, 551-553.
70. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, Kandoth C, Payton JE, Baty J, Welch J, et al.,. (2010) DNMT3A mutations in acute myeloid leukemia. N Engl J Med 363, 2424-2433.
71. Marcucci G, Metzeler KH, Schwind S, Becker H, Maharry K, Mrozek K, Radmacher MD, Kohlschmidt J, Nicolet D, Whitman SP, et al.,. (2012) Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol 30, 742-750.
72. Thol F, Damm F, Ludeking A, Winschel C, Wagner K, Morgan M, Yun H, Gohring G, Schlegelberger B, Hoelzer D, et al.,. (2011) Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol 29, 2889-2896.
73. Yan XJ, Xu J, Gu ZH, Pan CM, Lu G, Shen Y, Shi JY, Zhu YM, Tang L, Zhang XW, et al.,. (2011) Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet 43, 309-315.
74. Holz-Schietinger C, Matje DM, &, Reich NO, (2012) Mutations in DNA methyltransferase (DNMT3A) observed in acute myeloid leukemia patients disrupt processive methylation. J Biol Chem 287, 30941-30951.
75. Suzuki MM, &, Bird A, (2008) DNA methylation landscapes: provocative insights from epigenomics. Nat Rev Genet 9, 465-476.
76. Issa JP, Baylin SB, &, Herman JG, (1997) DNA methylation changes in hematologic malignancies: biologic and clinical implications. Leukemia 11 (Suppl 1), S7-11.
77. Santini V, Kantarjian HM, &, Issa JP, (2001) Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med 134, 573-586.
78. Conway O'Brien E, Prideaux S, &, Chevassut T, (2014) The epigenetic landscape of acute myeloid leukemia. Adv Hematol 2014, 103175.
79. Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, Gupta V, Kennedy JA, Schimmer AD, Schuh AC, Yee KW, et al.,. (2014) Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 506, 328-333.
80. Wu H, &, Zhang Y, (2011) Mechanisms and functions of Tet protein-mediated 5-methylcytosine oxidation. Genes Dev 25, 2436-2452.
81. Tan L, &, Shi YG, (2012) Tet family proteins and 5-hydroxymethylcytosine in development and disease. Development 139, 1895-1902.
82. Ko M, Huang Y, Jankowska AM, Pape UJ, Tahiliani M, Bandukwala HS, An J, Lamperti ED, Koh KP, Ganetzky R, et al.,. (2010) Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 468, 839-843.
83. Abdel-Wahab O, &, Levine RL, (2013) Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. Blood 121, 3563-3572.
84. Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, Agarwal S, Iyer LM, Liu DR, Aravind L, et al.,. (2009) Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324, 930-935.
85. Booth MJ, Ost TW, Beraldi D, Bell NM, Branco MR, Reik W, &, Balasubramanian S, (2013) Oxidative bisulfite sequencing of 5-methylcytosine and 5-hydroxymethylcytosine. Nat Protoc 8, 1841-1851.
86. Patel KP, Ravandi F, Ma D, Paladugu A, Barkoh BA, Medeiros LJ, &, Luthra R, (2011) Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features. Am J Clin Pathol 135, 35-45.
87. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, Yu W, Li Z, Gong L, Peng Y, et al.,. (2009) Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 324, 261-265.
88. Im AP, Sehgal AR, Carroll MP, Smith BD, Tefferi A, Johnson DE, &, Boyiadzis M, (2014) DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. Leukemia. 28, 1774-1783.
89. Koivunen P, Lee S, Duncan CG, Lopez G, Lu G, Ramkissoon S, Losman JA, Joensuu P, Bergmann U, Gross S, et al.,. (2012) Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 483, 484-488.
90. Losman JA, &, Kaelin WG Jr, (2013) What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev 27, 836-852.
91. Katoh M, (2013) Functional and cancer genomics of ASXL family members. Br J Cancer 109, 299-306.
92. Lee SW, Cho YS, Na JM, Park UH, Kang M, Kim EJ, &, Um SJ, (2010) ASXL1 represses retinoic acid receptor-mediated transcription through associating with HP1 and LSD1. J Biol Chem 285, 18-29.
93. Nasmyth K, &, Haering CH, (2009) Cohesin: its roles and mechanisms. Annu Rev Genet 43, 525-558.
94. Peters JM, Tedeschi A, &, Schmitz J, (2008) The cohesin complex and its roles in chromosome biology. Genes Dev 22, 3089-3114.
95. The Cancer Genome Atlas Research Network (2013) Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 368, 2059-2074. doi: 10.1056/NEJMoa1301689.
96. Leeke B, Marsman J, O'Sullivan JM, &, Horsfield JA, (2014) Cohesin mutations in myeloid malignancies: underlying mechanisms. Exp Hematol Oncol 3, 13.
97. Kon A, Shih LY, Minamino M, Sanada M, Shiraishi Y, Nagata Y, Yoshida K, Okuno Y, Bando M, Nakato R, et al.,. (2013) Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. Nat Genet 45, 1232-1237.
98. Thota S, Viny AD, Makishima H, Spitzer B, Radivoyevitch T, Przychodzen B, Sekeres MA, Levine RL, &, Maciejewski JP, (2014) Genetic alterations of the cohesin complex genes in myeloid malignancies. Blood 124, 1790-1798.
99. Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, Racevskis J, Dewald GW, Ketterling RP, Bennett JM, et al.,. (2009) Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 361, 1249-1259.
100. Lowenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Maertens J, Jongen-Lavrencic M, von Lilienfeld-Toal M, et al.,. (2009) High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 361, 1235-1248.
101. Lowenberg B, Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Biemond BJ, Gratwohl A, et al.,. (2011) Cytarabine dose for acute myeloid leukemia. N Engl J Med 364, 1027-1036.
102. Mercurio C, Minucci S, &, Pelicci PG, (2010) Histone deacetylases and epigenetic therapies of hematological malignancies. Pharmacol Res 62, 18-34.
103. Nebbioso A, Carafa V, Benedetti R, &, Altucci L, (2012) Trials with 'epigenetic' drugs: an update. Mol Oncol 6, 657-682.
104. Leone G, D'Alo F, Zardo G, Voso MT, &, Nervi C, (2008) Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias. Curr Med Chem 15, 1274-1287.
105. Espada J, Ballestar E, Fraga MF, Villar-Garea A, Juarranz A, Stockert JC, Robertson KD, Fuks F, &, Esteller M, (2004) Human DNA methyltransferase 1 is required for maintenance of the histone H3 modification pattern. J Biol Chem 279, 37175-37184.
106. Soncini M, Santoro F, Gutierrez A, Frige G, Romanenghi M, Botrugno OA, Pallavicini I, Pelicci P, Di Croce L, &, Minucci S, (2013) The DNA demethylating agent decitabine activates the TRAIL pathway and induces apoptosis in acute myeloid leukemia. Biochim Biophys Acta 1832, 114-120.
107. Stankov MV, El Khatib M, Kumar Thakur B, Heitmann K, Panayotova-Dimitrova D, Schoening J, Bourquin JP, Schweitzer N, Leverkus M, Welte K, et al.,. (2014) Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy. Leukemia 28, 577-588.
108. Quintas-Cardama A, Santos FP, &, Garcia-Manero G, (2011) Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Leukemia 25, 226-235.
109. Brogdon JL, Xu Y, Szabo SJ, An S, Buxton F, Cohen D, &, Huang Q, (2007) Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood 109, 1123-1130.
110. Kim MS, Kwon HJ, Lee YM, Baek JH, Jang JE, Lee SW, Moon EJ, Kim HS, Lee SK, Chung HY, et al.,. (2001) Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 7, 437-443.
111. Marks PA, Richon VM, &, Rifkind RA, (2000) Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92, 1210-1216.
112. Santoro F, Botrugno OA, Dal Zuffo R, Pallavicini I, Matthews GM, Cluse L, Barozzi I, Senese S, Fornasari L, Moretti S, et al.,. (2013) A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance. Blood 121, 3459-3468.
113. Thurn KT, Thomas S, Moore A, &, Munster PN, (2011) Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol 7, 263-283.
114. Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC, Wartman LD, Lamprecht TL, Liu F, Xia J, et al.,. (2012) The origin and evolution of mutations in acute myeloid leukemia. Cell 150, 264-278.
115. Leiva M, Moretti S, Soilihi H, Pallavicini I, Peres L, Mercurio C, Dal Zuffo R, Minucci S, &, de The H, (2012) Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL. Leukemia 26, 1630-1637.
116. Mohn F, Weber M, Rebhan M, Roloff TC, Richter J, Stadler MB, Bibel M, &, Schubeler D, (2008) Lineage-specific polycomb targets and de novo DNA methylation define restriction and potential of neuronal progenitors. Mol Cell 30, 755-766.
117. Yamazaki J, Estecio MR, Lu Y, Long H, Malouf GG, Graber D, Huo Y, Ramagli L, Liang S, Kornblau SM, et al.,. (2013) The epigenome of AML stem and progenitor cells. Epigenetics 8, 92-104.
118. Raynal NJ, Si J, Taby RF, Gharibyan V, Ahmed S, Jelinek J, Estecio MR, &, Issa JP, (2012) DNA methylation does not stably lock gene expression but instead serves as a molecular mark for gene silencing memory. Cancer Res 72, 1170-1181.
119. Laribee RN, &, Klemsz MJ, (2001) Loss of PU.1 expression following inhibition of histone deacetylases. J Immunol 167, 5160-5166.
120. Milhem M, Mahmud N, Lavelle D, Araki H, DeSimone J, Saunthararajah Y, &, Hoffman R, (2004) Modification of hematopoietic stem cell fate by 5aza 2′deoxycytidine and trichostatin A. Blood 103, 4102-4110.
121. Zardo G, Cimino G, &, Nervi C, (2008) Epigenetic plasticity of chromatin in embryonic and hematopoietic stem/progenitor cells: therapeutic potential of cell reprogramming. Leukemia 22, 1503-1518.
122. Schenk T, Chen WC, Gollner S, Howell L, Jin L, Hebestreit K, Klein HU, Popescu AC, Burnett A, Mills K, et al.,. (2012) Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat Med 18, 605-611.
123. Mack GS, (2010) To selectivity and beyond. Nat Biotechnol 28, 1259-1266.
124. Valente S, &, Mai A, (2014) Small-molecule inhibitors of histone deacetylase for the treatment of cancer and non-cancer diseases: a patent review (2011-2013). Expert Opin Ther Pat 24, 401-415.